肝癌电子杂志 ›› 2023, Vol. 10 ›› Issue (2): 27-32.

• 论著 • 上一篇    下一篇

2019年山西省肿瘤登记地区肝癌发病与死亡情况分析

郭雪蓉, 曹凌, 张瑞锋, 王昕琛, 乔楠, 张永贞*   

  1. 中国医学科学院肿瘤医院山西医院肿瘤防控办公室,山西太原 030013
  • 收稿日期:2023-04-25 出版日期:2023-06-30 发布日期:2023-08-14
  • 通讯作者: *张永贞,E-mail:zyzzhang2003@163.com
  • 作者简介:张永贞,中国医学科学院肿瘤医院山西医院,肿瘤防控办公室

Analysis of incidence and mortality of liver cancer in Shanxi cancer registries, 2019

Guo Xuerong, Cao Ling, Zhang Ruifeng, Wang Xinchen, Qiao Nan, Zhang Yongzhen*   

  1. Office of National Central Cancer Registry, Cancer Hospital & Shanxi Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Taiyuan 030013, Shanxi, China
  • Received:2023-04-25 Online:2023-06-30 Published:2023-08-14

摘要: 目的: 分析2019年山西省肿瘤登记地区肝癌发病与死亡情况,为制定肝癌防治策略提供依据。
方法:根据《中国肿瘤登记工作指导手册》,并参照国际癌症研究中心(International Agency for Research on Cancer,IARC)/国际癌症登记协会(International Association of Cancer Registries,IACR)制定的数据质量审核评价标准,对山西省符合质量控制标准要求的肿瘤登记点上报的肝癌发病、死亡和人口数据进行汇总分析,按性别、城乡地区和年龄分层计算粗发病率/死亡率、标化发病率/死亡率、0~74岁累积发病率/死亡率等指标。中国人口标化率(简称中标率)及世界人口标化率(简称世标率)分别采用2000年中国标准人口年龄构成和Segi世界标准人口年龄构成计算。
结果:2019年山西省肿瘤登记地区共有肝癌新发病例644例,粗发病率为13.18/10万,中标发病率为8.13/10万,世标发病率为8.30/10万,0~74岁累积发病率为0.96%,占全部恶性肿瘤发病的5.39%,位居恶性肿瘤发病第7位,标化后男女发病比为2.46∶1,城乡地区发病比为0.99∶1;肝癌死亡病例791例,粗死亡率为16.19/10万,中标死亡率为9.90/10万,世标死亡率为10.06/10万,0~74岁累积死亡率为1.16%,占全部恶性肿瘤死亡的10.00%,位居恶性肿瘤死亡第4位,标化后男女死亡比为1.90∶1,城乡地区死亡比为0.78∶1。肝癌发病率和死亡率随着年龄的增加呈上升趋势,在0~39岁处于较低水平,40岁以后快速上升,均在85+岁达到高峰,且男性高于女性。
结论:山西省肿瘤登记地区肝癌发病率和死亡率均低于全国平均水平,需将农村地区人口及男性作为肝癌防治的重点对象,推进肝癌早诊早治,提高早期肝癌的检出率,减轻肝癌的发病与死亡造成的疾病负担。

关键词: 肝癌, 发病率, 死亡率, 肿瘤登记, 山西省

Abstract: Objective: To analyze the incidence and mortality of liver cancer in Shanxi cancer registries in 2019, and to provide the strategies of prevention and treatment of liver cancer.
Method: According to the "Chinese Guideline for Cancer Registration" and referring to the data quality audit evaluation standards formulated by the International Agency for Research on Cancer (IARC)/International Association of Cancer Registration (IACR), a summary analysis was conducted on the incidence, death, and population data of liver cancer reported by tumor registration points in Shanxi Province that meet the quality control standards. The incidence/mortality crude rate, standardized incidence/mortality rate, and the cumulative rate of 0-74 years old were calculated by gender, area (urban and rural), and age. The age-standardized of Chinese standard population (ASR China) and world standard population (ASR world) were calculated by the Chinese standard population in 2000 and Segi's population, respectively.
Result: In 2019, 644 new cases of liver cancer were recorded in Shanxi cancer registries, accounting for 5.39% of all new cancer cases. The crude incidence rate was 13.18 per 100 000, with ASR China of 8.13 per 100 000 and ASR world of 8.30 per 100 000, respectively. The cumulative incidence rate (0-74 years old) was 0.96%. Liver cancer was the 7th most common cancer in the registration areas of China in 2019. The incidence of ASR China was 2.46 times in males as that in females, and it was 0.99 times in urban areas as that in rural areas. A total of 791 cases died of liver cancer in Shanxi cancer registries, accounting for 10.00% of all cancer deaths. The crude mortality rate was 16.19 per 100 000, with ASR China of 9.90 per 100 000 and ASR world of 10.06 per 100 000. The cumulative mortality rate (0-74 years old) was 1.16%. Liver cancer was the 4th most common cause of cancer deaths in the registration areas of China in 2019. The mortality of ASR China was 1.90 times in males as that in females, and it was 0.78 times in urban areas as that in rural areas. The incidence and mortality of liver cancer both increased with age, and the incidence increased more significantly after the age of 40. The incidence and mortality in Shanxi Province reached the peak in the age group of 85 years, and the male was higher than the female.
Conclusion: The incidence and mortality rates of liver cancer in Shanxi cancer registries are lower than national average, the male is higher than the female, and higher in rural areas than in urban areas. Therefore, the prevention and treatment of liver cancer should focus on males and pelple in rural areas. Early diagnosis and treatment of liver cancer should be promoted to increase the detection rate of early liver cancer and reduce the disease burden caused by liver cancer.

Key words: Liver cancer, Incidence, Mortality, Cancer registries, Shanxi Province